Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lalezari

Showing results (111-120 of 128) with videos related to

Pageof 13
Sort By:
AIDS Research and Human Retroviruses|August 9, 2002
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adultsJ Michael Kilby, Jacob P Lalezari, Joseph J Eron, et al.
Contemporary Clinical Trials|November 11, 2025
Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIVAna Gabriela Pires Dos Santos, Manal Abunimeh, Beatriz Mothe, et al.
Antiviral Therapy|October 2, 2003
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adultsJacob P Lalezari, Edwin DeJesus, Donald W Northfelt, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 19, 2008
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapyRichard T Davey, Peter E Pertel, Alice Benson, et al.
Antimicrobial Agents and Chemotherapy|May 21, 1998
Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study GroupJ W Gnann, C S Crumpacker, J P Lalezari, et al.
The Lancet. HIV|October 2, 2015
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trialJacob P Lalezari, Gulam H Latiff, Cynthia Brinson, et al.
Journal of Translational Autoimmunity|February 1, 2021
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimabNicholas Agresti, Jacob P Lalezari, Phillip P Amodeo, et al.
The Lancet. HIV|October 31, 2020
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE studyMax Lataillade, Jacob P Lalezari, Michael Kozal, et al.
HIV Clinical Trials|October 9, 2001
Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trialJ P Lalezari, J A Beal, P J Ruane, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 3, 1998
Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDSJ P Lalezari, G N Holland, F Kramer, et al.
Pageof 13

Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
AIDS Research and Human Retroviruses|August 9, 2002
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adultsJ Michael Kilby, Jacob P Lalezari, Joseph J Eron, et al.
Contemporary Clinical Trials|November 11, 2025
Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIVAna Gabriela Pires Dos Santos, Manal Abunimeh, Beatriz Mothe, et al.
Antiviral Therapy|October 2, 2003
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adultsJacob P Lalezari, Edwin DeJesus, Donald W Northfelt, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 19, 2008
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapyRichard T Davey, Peter E Pertel, Alice Benson, et al.
Antimicrobial Agents and Chemotherapy|May 21, 1998
Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study GroupJ W Gnann, C S Crumpacker, J P Lalezari, et al.
The Lancet. HIV|October 2, 2015
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trialJacob P Lalezari, Gulam H Latiff, Cynthia Brinson, et al.
Journal of Translational Autoimmunity|February 1, 2021
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimabNicholas Agresti, Jacob P Lalezari, Phillip P Amodeo, et al.
The Lancet. HIV|October 31, 2020
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE studyMax Lataillade, Jacob P Lalezari, Michael Kozal, et al.
HIV Clinical Trials|October 9, 2001
Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trialJ P Lalezari, J A Beal, P J Ruane, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 3, 1998
Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDSJ P Lalezari, G N Holland, F Kramer, et al.
Pageof 13